Showing results 1 to 1 of 1
Issue Date | Title | Journal Title |
---|---|---|
2023 | Randomized, two-arm, noncomparative phase 2 study of olaparib plus cediranib or durvalumab in HRR-mutated, platinum-resistant ovarian cancer: A substudy of KGOG 3045 | INTERNATIONAL JOURNAL OF CANCER |